{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=5&state=California", "query": { "state": "California", "city": "Fullerton", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1115, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=6&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=4&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T08:23:31.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01106690", "title": "The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 344, "start_date": "2010-06", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2013-07-15", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 41, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106690" }, { "nct_id": "NCT07614776", "title": "A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration", "nAMD" ], "interventions": [ { "name": "ABP 938 8 mg", "type": "DRUG" }, { "name": "Aflibercept (US) 8 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 304, "start_date": "2026-05-27", "completion_date": "2028-01-12", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 55, "location_summary": "Fullerton, California • Long Beach, California • Modesto, California + 50 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07614776" }, { "nct_id": "NCT03816163", "title": "A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 393, "start_date": "2019-03-15", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 25, "location_summary": "Fullerton, California • Whittier, California • Meriden, Connecticut + 22 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Meriden", "state": "Connecticut" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816163" }, { "nct_id": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2018-01-23", "completion_date": "2027-01-21", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 429, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03269669" }, { "nct_id": "NCT03412773", "title": "A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 684, "start_date": "2017-12-18", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Orange, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412773" }, { "nct_id": "NCT00347581", "title": "A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Convergence Insufficiency" ], "interventions": [ { "name": "Base-in prism glasses for reading", "type": "PROCEDURE" }, { "name": "Placebo reading glasses", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Pennsylvania College of Optometry", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "9 Years to 18 Years" }, "enrollment_count": 72, "start_date": "2003-05", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2006-07-04", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Fullerton, California • Fort Lauderdale, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00347581" }, { "nct_id": "NCT01416181", "title": "A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "natalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "58 Years", "sex": "ALL", "summary": "18 Years to 58 Years" }, "enrollment_count": 889, "start_date": "2011-09-13", "completion_date": "2016-04-13", "has_results": true, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416181" }, { "nct_id": "NCT06047457", "title": "A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Episodic Migraine" ], "interventions": [ { "name": "Botulinum toxin type A", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 751, "start_date": "2023-09-29", "completion_date": "2026-11-16", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047457" }, { "nct_id": "NCT05629962", "title": "SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)", "COVID-19" ], "interventions": [ { "name": "Bemnifosbuvir (BEM)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atea Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2022-11-25", "completion_date": "2024-05-30", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 61, "location_summary": "Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05629962" }, { "nct_id": "NCT06691984", "title": "Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Xaluritamig", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 707, "start_date": "2024-12-09", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-25T08:23:31.197Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06691984" } ] }